2023 World Conference on Lung Cancer (Posters)-EP07.05. Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions

EP07.05. Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions - PDF(Slides)

Back to course

Pdf Summary

Aumolertinib, a third-generation oral Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor, has shown promising results as an adjuvant treatment for non-small cell lung cancer (NSCLC) in previous studies. This study aimed to investigate the efficacy and safety of aumolertinib as adjuvant therapy in postoperative NSCLC patients with EGFR mutations, focusing on its effectiveness on unresected persistent ground-glass opacity (GGO) lesions.<br /><br />The study included 59 patients with pathologically confirmed adenocarcinoma, EGFR mutation-positive NSCLC. As of the cut-off date, all patients were alive with no tumor recurrence. Follow-up data showed a 1-year disease-free survival rate of 100%. No grade 3 adverse events occurred during aumolertinib treatment, and no patients withdrew from therapy due to adverse events.<br /><br />Among the patients with multiple GGO lesions after surgery, 66.7% showed a response to postoperative aumolertinib treatment, with a reduction in size or complete disappearance of the lesions. Notably, one patient had three residual GGO lesions, all of which completely disappeared.<br /><br />The study concludes that aumolertinib is highly effective as a postoperative adjuvant treatment for NSCLC, with a good safety profile. It also suggests the potential therapeutic efficacy of aumolertinib for patients with persistent GGO lesions. However, due to the limited number of patients with GGO lesions in this study, further research with a larger sample size is needed. Additionally, verifying the presence of EGFR mutations in GGO lesions can enhance the benefits of tyrosine kinase inhibitor treatment. The study is still ongoing, aiming to expand the number of patients with GGO lesions and extend the follow-up period for longer-term outcomes.<br /><br />The study acknowledges the study participants, their families, and caregivers, as well as the study team members and all staff involved in the trial.

Asset Subtitle

Haitao Ma

Meta Tag

Speaker Haitao Ma

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

Aumolertinib

oral EGFR tyrosine kinase inhibitor

adjuvant treatment

non-small cell lung cancer

NSCLC

EGFR mutations

ground-glass opacity lesions

disease-free survival rate

adverse events

postoperative treatment